Federal health officials are investigating whether the blood thinner Plavix - the world's second-best-selling drug and used by millions to reduce the risk of heart attack and stroke - may be less effective in some patients.
The Food and Drug Administration said Monday it is reviewing reports that certain heartburn medications can neutralize the benefits of Plavix. The agency said it is also investigating whether patients from certain genetic backgrounds also don't reap the drug's benefits.
In both cases, FDA said patients may have trouble metabolizing Plavix, reducing its ability to prevent deadly blood clots.
Plavix had global sales of $7.3 billion in 2007. The drug is marketed by Bristol-Myers Squibb Co. (BMY) (BMY) and Sanofi-Aventis SA (SNY) (SNY) and has been prescribed to more than 90 million patients around the world.
In November, researchers found that taking Plavix with popular prescription heartburn drugs like AstraZeneca PLC' (AZN)s Nexium significantly increased patients' chances of being hospitalized for a heart attack, stroke or chest pain. The researchers suggested that the heartburn drugs might interfere with a liver enzyme needed to metabolize Plavix.
However, some heart experts were skeptical of the findings. They noted that patients taking heartburn drugs may already have health problems that skew their risk for heart attack and other problems.
Doctors prescribe so-called proton pump inhibitor drugs to treat heartburn, in which painful stomach acids come back up the esophagus. Because Plavix, known generically as clopidogrel, can upset the stomach, it is often prescribed with the acid-blocking drugs, which include Wyeth' (WYE)s Protonix.
FDA said in a statement it is important to determine how the drugs interact because "decreases in the effectiveness of clopidogrel might be avoided, in part, by using other drugs ... that do not interfere with its metabolism."
FDA said there is no evidence that the "H2 blocker" family of heartburn drugs counteract Plavix. Those drugs include Johnson & Johnson' (JNJ) (JNJ)s Pepcid, Boehringer Ingelheim's Zantac and GlaxoSmithKline's Tagamet HB.
Sanofi-Aventis and Bristol-Myers Squibb said they are conducting studies of whether genetic factors or heartburn drugs can interfere with Plavix.
"Individuals do not all respond to the same degree to a specific drug," said Sanofi spokeswoman Elizabeth Baxter. "Many studies are currently ongoing, including studies of clopidogrel, to explore what is responsible for this phenomenon."
The studies will take several months to complete, according to FDA, which said it would issue recommendations after reviewing them.
Until more information is available, the FDA says patients should continue taking Plavix. However, doctors should be cautious when prescribing the heartburn drugs to patients already taking Plavix.
In general, the FDA has begun notifying the public earlier about possible safety issues involving drugs. The policy change came after the agency was criticized for acting too slowly on information about medicines that were later removed from the market due to safety reasons.
Shares of Paris-based Sanofi-Aventis rose 23 cents Monday to $30.60 in midday trading. Shares of New York-based Bristol-Myers Squibb Co. dipped 1 cent to $22.38.
Medical News
-
Vermont passes law allowing doctor-assisted suicide
Vermont on Monday became the fourth U.S. state to end legal penalties for doctors who prescribe medication to terminally ill patients seeking to end their own lives. -
'Uninsurables' at risk as states fear losing health aid
Thousands of people with serious medical problems are in danger of losing coverage under President Barack Obama's health care overhaul because of cost overruns, state officials say. -
Your kitchen isn't as clean as you think!
If you're a smoothie lover, take note. Eight spots in your kitchen -- including your blender -- may be alive with foodborne pathogens potent enough to sicken you and your family, a new study finds.
-
'Rapid strides': Advances offer hope for amputees
It will be weeks, at least, before Celeste Corcoran is anywhere near ready to think about artificial limbs. The 47-year-old Lowell, Mass.
-
FDA ups pressure on compounding pharmacies
The Food and Drug Administration is stepping up pressure on firms that make drugs for specific individuals, known as compounding pharmacies, as it seeks greater regulatory authority following a deadly meningitis outbreak traced to one such pharmacy.
-
Report questioning salt guidelines riles heart experts
An unusual medical brawl erupted on Tuesday when the influential Institute of Medicine issued a report questioning the basis of years of advice for Americans to cut their salt intake in half. -
Chris Christie's weight-loss procedure doesn't always work
New Jersey Gov. Chris Christie revealed that he's had gastric-band weight-loss surgery, which experts say has the least amount of short-term risk but also yields the least amount of weight loss.
-
Caffeinated gum raises health buzz
A new line of caffeinated chewing gum is causing jitters among health advocates and prompting federal officials to take a new look at the proliferation of jolt-infused foods, including those marketed to children and teens.
-
Dr. Oz's tips for losing those last 10 pounds
Stress, the slowing of metabolism of middle age, and hormone changes after having a baby are three main reasons why many people see the numbers on the scale going up. Dr. Mehmet Oz shares tips on how to shed those final 10 pounds.
-
How First Lady won over Miss. on school lunches
Despite its deeply red political leanings, it was Mississippi that early on embraced the first lady’s ideas about healthy food, and was the site where Mrs. Obama kicked off a two day, three-city tour touting the three-year anniversary of her “Let’s Move” initiative, which encourages kids to get and stay fit.
-
Anger may raise heart attack risk, study finds
Bottling up emotions is thought to harm both mind and body, but a new study suggests that the opposite extreme may be no better. -
Just one daily soda can raise diabetes risk
Drinking just one 12-ounce soda a day may increase the risk of Type 2 diabetes, a new study from Europe suggests. -
Gut bugs linked to heart attacks, strokes
Thousands of heart attack victims every year have none of the notorious risk factors before their crisis - not high cholesterol, not unhealthy triglycerides. -
12 school football players die each year, study finds
Each year in the U.S. an average of a dozen high school and college football players die during practices and games, according to a new study that finds heart conditions, heat and other non-traumatic causes of death are twice as common as injury-related ones. -
Chelation little help for heart disease: study
NEW YORK (Reuters Health) - Removing metals from the body through a controversial treatment has little effect on the long-term health of people who've previously suffered a heart attack, according to the results of a government-funded trial released Tuesday.
-
Brisk walk may be as good as a run, study finds
Walking really is just as good for you as running – but only if you compare it in terms of calories burned and not merely on time spent, researchers reported on Thursday. -
Smart jocks: Fit kids do better at math, reading
Forget the old high school clichés about athletes not doing as well academically as less sporty kids -- a new study shows that children who exercise more do better in math, reading tests.
-
Seeing green might make your workout better
The positive effects of green exercise may have more to do with the color green than with being surrounded by nature, according to a new study. -
No time to exercise? Try 10-minute workouts
The procrastinators, the super-busy, and the easily bored in pursuit of a manageable fitness routine may find what they seek in the 10-minute workout.
-
Stressed? Exercise may help ward off anxiety
Exercise not only improves mood, it may help people maintain reduced anxiety in the face of stressful or emotional events, a new study says.
